Dizal Pharmaceutical released its performance for the first three quarters, with a net loss attributable to the parent company of 580 million yuan

According to the Zhitong Finance APP, Dizal Pharmaceutical disclosed its third-quarter report for 2025, stating that the company achieved revenue of 586 million yuan in the first three quarters, a year-on-year increase of 73.23%; the net profit attributable to the parent company was a loss of 580 million yuan; the net profit excluding non-recurring gains and losses was a loss of 631 million yuan; and the basic earnings per share were -1.32 yuan